Complete DNA analysis for young adults with cancer
KWF finances the expansion of the infrastructure for cancer research in young adults with almost 4.5 million euros. These are young people aged 18 to 39, also known as AYAs: Adolescents and Young Adults. With this grant, Hartwig Medical Foundation will use the latest techniques to visualize the complete DNA of the tumor for 1,000 patients over the next four years. This means that the treatment can be better attuned to the specific tumor characteristics of each patient.
GENAYA
The genetic information and treatment data are stored with the patient’s consent in a globally unique database and made available for scientific research. In this way, not only these 1,000 patients will benefit from the research, but also the patients in the future. The project named GENAYA (a national database of GENome data of Adolescent and Young Adult cancers) builds on an infrastructure already funded by KWF; COMPRAYA. Hartwig Medical Foundation will provide diagnostic DNA analysis based on whole genome sequencing for GENAYA. Thanks to the grant from KWF, the complete DNA analysis are also made available to AYA patients in non-academic centers.
Hartwig Medical Foundation
Hartwig Medical is a not-for-profit foundation. The foundation aims to improve care for patients with cancer. It does this by advancing cancer research and conducting complete DNA analysis in cancer patients. This should contribute to ensuring that every cancer patient receives the treatment that best suits her or him.
More information
- Complete DNA test
- Hartwig Medical database
- Publications with data from Hartwig Medical database
All news
Also read
Actionable metastatic cancer genome is remarkably stable over time, despite treatment with drugs
A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be …
GenomeWeb: ‘Dutch Team Looks to Drug Repurposing to Improve Patient Outcomes, Lower Costs’
The project is an attempt to address the rising healthcare costs associated with new cancer drugs and to identify biomarkers …
ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk …
I know how important knowledge of hereditary predisposition to cancer can be. This is why I think it is so important that comprehensive patient reports include precisely that carrier information, if the patient wishes to be informed of it.